HELX ETF
Franklin Genomic Advancements ETF
HELX ETF Overview
HELX ETF (Franklin Genomic Advancements ETF) is managed by Franklin Templeton Investments (US) with $33.3M in net assets. HELX expense ratio is 0.50%, holding 70 positions across sectors including Health Care, Information Technology, Materials. Inception date: 2020-02-25.
HELX performance shows a YTD return of 15.20%. The 1-year return is 41.46% and the 5-year return is -5.48%.
HELX top holdings include Guardant Health, Inc (9.3%), Natera Inc (8.8%), Krystal Biotech Inc (5.8%), Ligand Pharmaceuticals, Inc. (4.4%), Adaptive Biotechnologies Corp (4.4%). Go to all HELX holdings, HELX sectors, or HELX dividends.
HELX can be compared against other funds. Use HELX overlap to find shared positions, or HELX vs another fund for a side-by-side view. HELX alternatives are available via the screener, along with tax-loss harvesting opportunities.